These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 22397573)

  • 1. An evaluation of oligonucleotide-based therapeutic strategies for polyQ diseases.
    Fiszer A; Olejniczak M; Switonski PM; Wroblewska JP; Wisniewska-Kruk J; Mykowska A; Krzyzosiak WJ
    BMC Mol Biol; 2012 Mar; 13():6. PubMed ID: 22397573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Silencing of genes responsible for polyQ diseases using chemically modified single-stranded siRNAs.
    Fiszer A; Ellison-Klimontowicz ME; Krzyzosiak WJ
    Acta Biochim Pol; 2016; 63(4):759-764. PubMed ID: 27770571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting several CAG expansion diseases by a single antisense oligonucleotide.
    Evers MM; Pepers BA; van Deutekom JC; Mulders SA; den Dunnen JT; Aartsma-Rus A; van Ommen GJ; van Roon-Mom WM
    PLoS One; 2011; 6(9):e24308. PubMed ID: 21909428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allele-selective inhibition of expression of huntingtin and ataxin-3 by RNA duplexes containing unlocked nucleic acid substitutions.
    Aiba Y; Hu J; Liu J; Xiang Q; Martinez C; Corey DR
    Biochemistry; 2013 Dec; 52(51):9329-38. PubMed ID: 24266403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allele-selective inhibition of mutant huntingtin expression with antisense oligonucleotides targeting the expanded CAG repeat.
    Gagnon KT; Pendergraff HM; Deleavey GF; Swayze EE; Potier P; Randolph J; Roesch EB; Chattopadhyaya J; Damha MJ; Bennett CF; Montaillier C; Lemaitre M; Corey DR
    Biochemistry; 2010 Nov; 49(47):10166-78. PubMed ID: 21028906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RNA duplexes with abasic substitutions are potent and allele-selective inhibitors of huntingtin and ataxin-3 expression.
    Liu J; Pendergraff H; Narayanannair KJ; Lackey JG; Kuchimanchi S; Rajeev KG; Manoharan M; Hu J; Corey DR
    Nucleic Acids Res; 2013 Oct; 41(18):8788-801. PubMed ID: 23887934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AAV-Mediated CAG-Targeting Selectively Reduces Polyglutamine-Expanded Protein and Attenuates Disease Phenotypes in a Spinocerebellar Ataxia Mouse Model.
    Niewiadomska-Cimicka A; Fievet L; Surdyka M; Jesion E; Keime C; Singer E; Eisenmann A; Kalinowska-Poska Z; Nguyen HHP; Fiszer A; Figiel M; Trottier Y
    Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oligonucleotide therapeutic approaches for Huntington disease.
    Sah DW; Aronin N
    J Clin Invest; 2011 Feb; 121(2):500-7. PubMed ID: 21285523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allele-specific quantitation of ATXN3 and HTT transcripts in polyQ disease models.
    Joachimiak P; Ciesiołka A; Kozłowska E; Świtoński PM; Figura G; Ciołak A; Adamek G; Surdyka M; Kalinowska-Pośka Ż; Figiel M; Caron NS; Hayden MR; Fiszer A
    BMC Biol; 2023 Feb; 21(1):17. PubMed ID: 36726088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients.
    Pfister EL; Kennington L; Straubhaar J; Wagh S; Liu W; DiFiglia M; Landwehrmeyer B; Vonsattel JP; Zamore PD; Aronin N
    Curr Biol; 2009 May; 19(9):774-8. PubMed ID: 19361997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allele-specific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs.
    Hu J; Matsui M; Gagnon KT; Schwartz JC; Gabillet S; Arar K; Wu J; Bezprozvanny I; Corey DR
    Nat Biotechnol; 2009 May; 27(5):478-84. PubMed ID: 19412185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ss-siRNAs allele selectively inhibit ataxin-3 expression: multiple mechanisms for an alternative gene silencing strategy.
    Liu J; Yu D; Aiba Y; Pendergraff H; Swayze EE; Lima WF; Hu J; Prakash TP; Corey DR
    Nucleic Acids Res; 2013 Nov; 41(20):9570-83. PubMed ID: 23935115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ataxin-3 protein modification as a treatment strategy for spinocerebellar ataxia type 3: removal of the CAG containing exon.
    Evers MM; Tran HD; Zalachoras I; Pepers BA; Meijer OC; den Dunnen JT; van Ommen GJ; Aartsma-Rus A; van Roon-Mom WM
    Neurobiol Dis; 2013 Oct; 58():49-56. PubMed ID: 23659897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allele-selective inhibition of mutant huntingtin by peptide nucleic acid-peptide conjugates, locked nucleic acid, and small interfering RNA.
    Hu J; Matsui M; Corey DR
    Ann N Y Acad Sci; 2009 Sep; 1175():24-31. PubMed ID: 19796074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained effects of nonallele-specific Huntingtin silencing.
    Drouet V; Perrin V; Hassig R; Dufour N; Auregan G; Alves S; Bonvento G; Brouillet E; Luthi-Carter R; Hantraye P; Déglon N
    Ann Neurol; 2009 Mar; 65(3):276-85. PubMed ID: 19334076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice.
    Boudreau RL; McBride JL; Martins I; Shen S; Xing Y; Carter BJ; Davidson BL
    Mol Ther; 2009 Jun; 17(6):1053-63. PubMed ID: 19240687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploring the effect of sequence length and composition on allele-selective inhibition of human huntingtin expression by single-stranded silencing RNAs.
    Hu J; Liu J; Yu D; Aiba Y; Lee S; Pendergraff H; Boubaker J; Artates JW; Lagier-Tourenne C; Lima WF; Swayze EE; Prakash TP; Corey DR
    Nucleic Acid Ther; 2014 Jun; 24(3):199-209. PubMed ID: 24694346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Artificial miRNAs targeting CAG repeat expansion in ORFs cause rapid deadenylation and translation inhibition of mutant transcripts.
    Ciesiolka A; Stroynowska-Czerwinska A; Joachimiak P; Ciolak A; Kozlowska E; Michalak M; Dabrowska M; Olejniczak M; Raczynska KD; Zielinska D; Wozna-Wysocka M; Krzyzosiak WJ; Fiszer A
    Cell Mol Life Sci; 2021 Feb; 78(4):1577-1596. PubMed ID: 32696070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polyglutamine (PolyQ) diseases: genetics to treatments.
    Fan HC; Ho LI; Chi CS; Chen SJ; Peng GS; Chan TM; Lin SZ; Harn HJ
    Cell Transplant; 2014; 23(4-5):441-58. PubMed ID: 24816443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allele-selective inhibition of huntingtin expression by switching to an miRNA-like RNAi mechanism.
    Hu J; Liu J; Corey DR
    Chem Biol; 2010 Nov; 17(11):1183-8. PubMed ID: 21095568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.